Article

Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Johns Hopkins SSc Center, Baltimore, MD 21224, USA.
Current Rheumatology Reports (Impact Factor: 2.45). 05/2006; 8(2):131-7. DOI: 10.1007/s11926-006-0053-z
Source: PubMed

ABSTRACT Vascular disease is universal in patients with systemic sclerosis (SSc), but there is a wide variability in its severity. It is clear that there is an early insult to the microvasculature, followed-up by on-going chronic process. This results in profound vascular damage in a subset of patients who develop severe events such as digital loss and pulmonary arterial hypertension. Although there is abundant evidence of vascular perturbation from studies of peripheral blood in SSc, there are few data about the ability to use these biomarkers to predict vascular outcomes. This paper examines the possibility of using circulating biomarkers to assess vascular disease activity and to predict severe vascular events among patients with SSc.

0 Followers
 · 
51 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: DEFINICIÓN Y CARACTERÍSTICAS GENERALES La escleroderma, también conocida como esclerosis sis-témica progresiva (ESP) es una enfermedad sistémica de causa desconocida que además de afectar la piel, involucra otros órganos de la economía como riñón, pul-món, corazón y aparato gastrointestinal. La palabra "es-cleroderma" proviene del Griego "skleros" que significa "duro" + "derma" que significa "piel" = piel dura; caracte-rística principal en la piel de estos pacientes a conse-cuencia de la acumulación de tejido conectivo (Figura 1). La ESP afecta 20 nuevos pacientes por millón por año y tiene una prevalencia estimada de 242 casos por millón en la población estadounidense. 1 Se presenta con más frecuencia entre los 45 y 64 años y como en casi todas las colagenopatías, ESP es más común en mujeres que en hombres (radio 6-8:1), sin em-RESUMEN. La escleroderma tiene una prevalencia de 242 casos por millón en los Estados Unidos. Uno de los órganos más afectados es el pulmón, siendo las manifestaciones más frecuentes la enfermedad pulmonar intersticial y la hipertensión arterial pulmonar. La enfermedad intersticial progresa a ser severa en cerca del 15% y hoy en día es la primera causa de muerte en pacientes con escleroderma, con una sobrevida media de 6.5 años después del diagnóstico. Los pacientes en mayor riesgo de desarrollar enfermedad intersticial son aquéllos con el tipo escleroderma difusa y con anticuerpos anti-SCL-70 positivos. En esta revisión, se discuten las manifestaciones radiográficas y patológicas de la fibrosis pulmonar asociada a escleroderma, la utilidad de las pruebas de función pulmonar y del lavado bronquioloalveolar para identificar la presencia de fibrosis y la decisión de a quiénes tratar. Aunque no del todo efectivos, ciclofosfamida o micofenolato ofrecen buena alternativa de tratamiento. Palabras clave: Escleroderma, enfermedad pulmonar intersticial (EIP), hipertensión arterial pulmonar (HAP), anticuerpos anti-SCL-70, ciclofosfamida, micofenolato.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic sclerosis is a complex, progressive autoimmune disease. The origin is, so far, unknown and it is characterized by immunological and endothelial damage followed by fibrosis. Interaction between the host genetic backgrounds with environmental factors is thought to turn out an abnormal immune response characterized by clonal expansion of Th2 repertoire, upregulation of pro-fibrotic cytokines and dysregulated B cells. Specific autoantibodies profiles are associated with clinical subtypes of the diseases. Endothelial activation is an early feature with damage of the vasocontrictive and vasodilation response. Finally, persistent tissue ischemia and abnormal immune response produce myofibroblast proliferation andoverproduction of extracellular matrix proteins and fibrosis.
    Reumatología Clínica 11/2006; 2. DOI:10.1016/S1699-258X(06)73100-X
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We hypothesize that pulmonary arterial hypertension (PAH)-associated genes identified by expression profiling of peripheral blood mononuclear cells (PBMCs) from patients with idiopathic pulmonary arterial hypertension (IPAH) can also be identified in PBMCs from scleroderma patients with PAH (PAH-SSc). Gene expression profiles of PBMCs collected from IPAH (n = 9), PAH-SSc (n = 10) patients, and healthy controls (n = 5) were generated using HG_U133A_2.0 GeneChips and were processed by the RMA/GCOS_1.4/SAM_1.21 data analysis pipeline. Disease severity in consecutive patients was assessed by functional status and hemodynamic measurements. The expression profiles were analyzed using PAH severity-stratification, and identified candidate genes were validated with real-time polymerase chain reaction (PCR). Transcriptomics of PBMCs from IPAH patients was highly comparable with that of PMBCs from PAH-SSc patients. The PBMC gene expression patterns significantly correlate with right atrium pressure (RA) and cardiac index (CI), which are known predictors of survival in PAH. Array stratification by RA and CI identified 364 PAH-associated candidate genes. Gene ontology (GO) analysis revealed significant (Z(score) > 1.96) alterations in angiogenesis genes according to PAH severity: matrix metalloproteinase 9 (MMP9) and vascular endothelial growth factor (VEGF) were significantly upregulated in mild as compared with severe PAH and healthy controls, as confirmed by real-time PCR. These data demonstrate that PBMCs from patients with PAH-SSc carry distinct transcriptional expression. Furthermore, our findings suggest an association between angiogenesis-related gene expression and severity of PAH in PAH-SSc patients. Deciphering the role of genes involved in vascular remodeling and PAH development may reveal new treatment targets for this devastating disorder.
    Translational Research 04/2008; 151(4):197-207. DOI:10.1016/j.trsl.2007.12.010 · 4.04 Impact Factor
Show more